Octreotide Acetate CAS 83150-76-9 Peptide Maʻemaʻe (HPLC) ≥98.0% API Kūlana Kiʻekiʻe

ʻO Octreotide Acetate (Sandostatin) kahi analogue peptide synthetic o ka hormone somatostatin, he analog somatostatin lōʻihi ia i hōʻike ʻia no ka hoʻokele symptomatic i nā maʻi acromegaly a me gastroenteropancreatic.ʻO nā mea hoʻohana ʻē aʻe ma lalo o ka hoʻokolokolo ʻana ʻo ia ka maʻi diabetes, psoriasis a me ka maʻi Alzheimer.ʻO Octreotide Acetate (Sandostatin) kahi analogue peptide synthetic o ka hormone somatostatin.ʻO kāna mau hana e pili ana i ka pale ʻana i ka huna pituitary o ka hormone ulu a me ka pale ʻana i ka huna ʻana o ka pancreatic islet cell huna o ka insulin a me ka glucagon.ʻAʻole like me ka somatostatin, nona ka hapalua o ke ola o ka plasma no kekahi mau minuke, aia ka Octreotide i ka hapalua o ka plasma elimination o 1 a 2 mau hola.ʻO ka excretion o ka lāʻau lapaʻau ma mua o ka renal.Hoʻemi ʻo Octreotide i ka neʻe ʻana o ka ʻōpū a hoʻopaʻa i ka ʻoki ʻana o ka ʻōpū.

ʻO nā lāʻau peptide Novartis Sandostatin (Octreotide Acetate), he synthetic natural somatostatin octapeptide derivatives, mālama ia i kahi hopena pharmacological e like me ka somatostatin, a lōʻihi ka hopena.ʻO nā hōʻailona no ka Octreotide Acetate he acromegaly;Hoʻopau i nā hōʻailona a me nā hōʻailona e pili ana i ka gastroenteropancreatic endocrine neoplasia;A me ka pono ma Carcinoid Tumors e hōʻike ana me ka maʻi carcinoid, nā ʻōpū VIP, a me nā maʻi glucagon.Eia kekahi, ʻo Octreotide Acetate no ka maʻi gastrinomas / Zollinger-Ellison (i hui pū ʻia me nā mea hoʻopaʻa proton pump a i ʻole H2 receptor blockers), Insulinomas (ka pale ʻana o ka hypoglycemia a me ka mālama ʻana i ke kō koko maʻamau), ʻo ka wikiwiki o ka ulu ʻana o ka hormone hoʻokuʻu ʻana i ka mea maʻi maʻi. ma kahi o 50%.

ʻO Octreotide Acetate kahi lāʻau lapaʻau olakino olakino ʻo Class B, he synthetic natural octapeptide derivative o somatostatin, i hoʻohālikelike ʻia me ka somatostatin maoli, ʻike ʻia ka lōʻihi o ka hapalua o ke ola o ka somatostatin a loaʻa nā hopena pharmacological like, me ka pale ʻana i ka hana hormone ulu, inhibition. o ka ʻakika ʻōpū, ka enzyme pancreatic, ka glucagon a me ka huna ʻana o ka insulin, a me ka hōʻemi ʻana o ke kahe koko visceral, hoʻemi i ka motility gastrointestinal.Ke hoʻohālikelike ʻia me ka somatostatin maoli, ʻo ka octreotide ka hapalua o ke ola, ʻoi aku ka koho no ka pale ʻana i ka ulu ʻana o ka hormone ma mua o ka pale ʻana i ka huna ʻana o ka insulin, ʻaʻole ia e hoʻihoʻi i ka hypersecretion o ka hormone.1, ʻAʻole hiki ke hoʻopaʻa pono i ka maʻi i nā maʻi me nā hōʻailona acromegaly a hoʻemi i ka hormone ulu o ka mea maʻi (GH) insulin-like growth factor -1(1GF-1) pae plasma.Hiki ke hoʻohana ʻia ʻo Sandostatin no ka mālama ʻana i nā poʻe maʻi me ka acromegaly hiki ʻole a makemake ʻole paha e hana i ka ʻokiʻoki, a i ʻole e mālama i nā maʻi me ka acromegaly ʻaʻole i loaʻa i ka radiation therapy.2. Ho'ēmi i nā hōʻailona e pili ana i nā maʻi ʻōpū endocrine gastroenteropancreatic (GEP) e like me nā maʻi maʻi carcinoid me nā hōʻike maʻi carcinoid.ʻAʻole ʻo Sandostatin kahi lāʻau anti-cancer a ʻaʻole hoʻōla i kēia mau maʻi.3, Kāohi ʻana i nā pilikia ma hope o ka ʻoki ʻana i ka pancreatic.4, ʻO nā maʻi cirrhosis ate me ke koko o ka ʻōpū-esophageal variceal ma muli o ka mālama ʻana i ka pilikia, hemostasis a me ka pale ʻana i ka rebleeding, pono e hui pū ʻia ʻo Sandostatin me ka sclerotherapy endoscopic a me nā lāʻau kūikawā ʻē aʻe.